Total Payments
$16,476
2024 Payments
$1,959
Companies
42
Transactions
435
Medicare Patients
16,661
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$11,737 (71.2%)
Consulting$4,136 (25.1%)
Travel$463.29 (2.8%)
Education$140.26 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,737 | 425 | 71.2% |
| Consulting Fee | $4,136 | 1 | 25.1% |
| Travel and Lodging | $463.29 | 2 | 2.8% |
| Education | $140.26 | 7 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,984 | 97 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,007 | 40 | $0 (2024) |
| Amgen Inc. | $1,006 | 26 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $855.50 | 55 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $830.57 | 27 | $0 (2024) |
| Novo Nordisk Inc | $764.98 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $685.86 | 26 | $0 (2024) |
| Boston Scientific Corporation | $585.59 | 11 | $0 (2023) |
| PFIZER INC. | $450.26 | 17 | $0 (2023) |
| Merck Sharp & Dohme LLC | $364.04 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,959 | 63 | Novo Nordisk Inc ($464.91) |
| 2023 | $1,406 | 56 | Novartis Pharmaceuticals Corporation ($202.85) |
| 2022 | $1,755 | 71 | Bayer HealthCare Pharmaceuticals Inc. ($556.03) |
| 2021 | $882.47 | 46 | AstraZeneca Pharmaceuticals LP ($231.76) |
| 2020 | $1,183 | 47 | AstraZeneca Pharmaceuticals LP ($340.30) |
| 2019 | $6,322 | 61 | Novartis Pharmaceuticals Corporation ($4,937) |
| 2018 | $1,659 | 47 | Novartis Pharmaceuticals Corporation ($426.88) |
| 2017 | $1,309 | 44 | Novartis Pharmaceuticals Corporation ($538.60) |
All Payment Transactions
435 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $98.99 | General |
| Category: Cardiology | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $30.45 | General |
| Category: Cardio-pulmonary | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $22.16 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/31/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $4.55 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/31/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $3.25 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/15/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $121.84 | General |
| 09/23/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/19/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.39 | General |
| Category: Cardiovascular | ||||||
| 09/05/2024 | VivaQuant Inc, dba Rhythm Express | Rhythm Express (Device) | Food and Beverage | Cash or cash equivalent | $15.27 | General |
| Category: Remote Cardiac Monitoring | ||||||
| 08/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $28.38 | General |
| Category: Cardio-pulmonary | ||||||
| 08/20/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $30.06 | General |
| Category: Cardiology | ||||||
| 08/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: DIABETES | ||||||
| 08/13/2024 | MEDICOMP INC | TELEPATCH CARDIAC MONITOR (Device) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: CARDIOLOGY | ||||||
| 08/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/30/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 5,070 | 8,478 | $1.4M | $407,295 |
| 2022 | 23 | 4,109 | 7,972 | $1.3M | $408,840 |
| 2021 | 26 | 3,915 | 5,675 | $1.3M | $402,256 |
| 2020 | 29 | 3,567 | 5,484 | $1.5M | $450,477 |
Total Patients
16,661
Total Services
27,609
Medicare Billing
$1.7M
Procedure Codes
113
All Medicare Procedures & Services
113 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 172 | 172 | $152,908 | $56,293 | 36.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 300 | 529 | $100,510 | $47,060 | 46.8% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 63 | 65 | $107,250 | $42,562 | 39.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 228 | 232 | $104,400 | $34,339 | 32.9% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 184 | 367 | $73,400 | $31,507 | 42.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 82 | 658 | $98,700 | $24,264 | 24.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 131 | 524 | $127,311 | $22,836 | 17.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 2,479 | 3,650 | $73,000 | $22,529 | 30.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 104 | 214 | $73,830 | $19,664 | 26.6% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 59 | 375 | $46,875 | $14,357 | 30.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 104 | 104 | $35,880 | $13,677 | 38.1% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 62 | 435 | $77,350 | $13,263 | 17.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 239 | 243 | $109,175 | $12,861 | 11.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 86 | 86 | $33,712 | $12,783 | 37.9% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 185 | 185 | $47,360 | $8,909 | 18.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 109 | 123 | $14,883 | $8,239 | 55.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 52 | 52 | $20,384 | $6,797 | 33.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 33 | $8,976 | $3,721 | 41.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 45 | $11,160 | $2,767 | 24.8% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 13 | 14 | $5,740 | $2,475 | 43.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 192 | 204 | $13,260 | $2,275 | 17.2% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 63 | 65 | $26,130 | $1,261 | 4.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 12 | $2,280 | $832.48 | 36.5% |
| 99091 | Collection and interpretation of physical parameters stored in computers and/or transmitted by the patient and/or caregiver to qualified health care professional, requiring 30 minutes or more, per 30 days | Office | 2023 | 13 | 16 | $1,600 | $672.80 | 42.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 13 | $1,170 | $573.69 | 49.0% |
About Dr. Seyed Hashemi, MD
Dr. Seyed Hashemi, MD is a Cardiovascular Disease healthcare provider based in Woodbridge, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831186790.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Seyed Hashemi, MD has received a total of $16,476 in payments from pharmaceutical and medical device companies, with $1,959 received in 2024. These payments were reported across 435 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($11,737).
As a Medicare-enrolled provider, Hashemi has provided services to 16,661 Medicare beneficiaries, totaling 27,609 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 113 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Woodbridge, VA
- Active Since 10/05/2005
- Last Updated 04/21/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1831186790
Products in Payments
- ENTRESTO (Drug) $1,915
- XARELTO (Drug) $855.50
- Repatha (Biological) $854.49
- Adempas (Drug) $705.77
- FARXIGA (Drug) $474.19
- LEQVIO (Drug) $410.02
- UPTRAVI (Drug) $375.19
- VERQUVO (Drug) $348.64
- Coala Heart Monitor (Device) $347.95
- OPSUMIT (Drug) $343.55
- ELIQUIS (Drug) $342.26
- JARDIANCE (Drug) $269.57
- LifeVest (Device) $262.71
- Wegovy (Drug) $247.52
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $244.67
- VYNDAQEL (Drug) $176.88
- OPSUMIT MACITENTAN (Drug) $163.65
- Ozempic (Drug) $160.85
- BRILINTA (Drug) $158.34
- Corlanor (Drug) $147.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Woodbridge
Vikaas Kataria, M.d, M.D
Cardiovascular Disease — Payments: $6,888
Cardiovascular Disease $6,888
Kambeez Berenji, Md, MD
Cardiovascular Disease — Payments: $5,952
Cardiovascular Disease $5,952
Dr. Mariano Chutuape, M.d, M.D
Cardiovascular Disease — Payments: $1,144
Cardiovascular Disease $1,144
Dr. Stuart Meyers, M.d, M.D
Cardiovascular Disease — Payments: $103.42
Cardiovascular Disease $103.42
Dr. Barkev Banian, M.d, M.D
Cardiovascular Disease — Payments: $13.42
Cardiovascular Disease $13.42
Richard Fearon
Cardiovascular Disease
Cardiovascular Disease